Rare Disease Drug Insurance Denied? How to Appeal

Rare disease drug denials are among the most medically urgent and legally complex insurance appeals. If your orphan drug, FDA-approved rare disease treatment, or specialty medication was denied — often on "experimental" or "not medically necessary" grounds — the Orphan Drug Act, FDA approval status, and NORD patient advocacy resources provide specific tools that most other medical claims do not have. Here is how to build a winning appeal.

Why Insurers Deny Rare Disease Drugs

The primary denial reasons for rare disease drugs are: "experimental or investigational" — the insurer's clinical policy bulletin has not recognized the drug despite FDA approval, which is legally incorrect for FDA-approved drugs used for their approved indication; "not medically necessary" — the insurer's criteria may not be calibrated to rare diseases, applying general medical necessity standards that do not reflect the disease-specific evidence base; step therapy requirements — insurers may require patients to try alternatives that do not exist for rare diseases, or to fail treatments that are inappropriate for their specific rare condition; Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization failures — rare disease drugs almost universally require pre-approval, and authorization gaps are common when PA policies for rare drugs are not well-established; and formulary non-coverage — the drug may not appear on the plan's formulary at all, requiring a formulary exception request.

How to Appeal a Rare Disease Drug Denial

Step 1: Confirm FDA Approval Status and Orphan Drug Designation

The foundation of your appeal for any FDA-approved rare disease drug is the drug's regulatory status. Under the Orphan Drug Act (21 U.S.C. § 360aa et seq.), the FDA grants orphan drug designation to drugs intended to treat rare diseases (fewer than 200,000 US patients). Once FDA-approved for its designated indication, an orphan drug is not experimental — and an insurer cannot legally deny coverage of an FDA-approved drug for its FDA-approved indication on grounds that it is "experimental." Cite the specific FDA approval date, the approved indication, and any orphan designation.

Step 2: Address Accelerated Approval and Breakthrough Therapy Designation

If your drug was approved under FDA Accelerated Approval or has Breakthrough Therapy Designation (21 U.S.C. § 356), insurers sometimes argue the evidence base is insufficient because accelerated approval uses surrogate endpoints. Your appeal must argue: the FDA's approval represents the agency's determination that benefits outweigh risks; insurers cannot substitute their own evidence standards for the FDA's; the accelerated approval pathway includes post-marketing commitment studies that constitute ongoing evidence generation; and denying a Breakthrough-designated drug based on insufficient evidence ignores the FDA's explicit finding of promising results in a serious condition.

Step 3: Obtain Treating Specialist Documentation

Your specialist's letter of medical necessity must: document your specific rare disease diagnosis with diagnostic codes; explain the clinical evidence base for the drug in your condition; address why standard or alternative treatments are not appropriate for your specific case; cite any published clinical guidelines, specialty society statements, or published case series supporting use of the drug; and explain the expected clinical outcomes and risks of continued denial.

Step 4: Contact NORD and Patient Advocacy Organizations

The National Organization for Rare Disorders (NORD) at rarediseases.org provides free insurance appeal assistance through its Rare Disease Patient Navigation program, disease-specific advocacy connections, patient assistance program information, and template appeal letters for rare disease denials. Many rare disease pharmaceutical manufacturers also operate patient assistance and insurance navigation programs through their medical affairs departments — contact the manufacturer directly.

Step 5: Challenge Prior Authorization Burden for Rare Diseases

When challenging PA for rare disease drugs, specifically argue: (1) the PA clinical criteria may not be calibrated to your specific rare disease — criteria written for common conditions frequently do not apply; (2) the plan's reviewing physician may lack expertise in the specific rare disease, which should be challenged on procedural grounds; (3) prior authorization delays for rare diseases can cause rapid and irreversible progression. Under most state and federal appeal regulations, you have the right to request peer-to-peer review with a physician who has subspecialty expertise in your rare disease.

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review — Critical for Rare Disease Appeals

External review under ACA Section 2719 (45 CFR § 147.138) is binding on the insurer. For rare diseases, the IRO must select a reviewer with appropriate expertise. IROs overturn rare disease denials at meaningful rates when FDA approval status, specialist documentation, and NORD resources are properly presented.

What to Include in Your Appeal

• FDA drug approval documentation and orphan drug designation
• Treating specialist's Letter of Medical Necessity with condition-specific evidence
• NORD resources, patient advocacy organization support letters, or disease registry data
• Prior treatment history showing why alternatives are not appropriate
• Step therapy exception law citation (if your state has one, particularly relevant for rare diseases with no alternatives)
• Expedited review request with documentation of urgent clinical need

Fight Back With ClaimBack

Rare disease drug denials involving FDA-approved medications are among the strongest candidates for successful appeal — the insurer's ability to call an FDA-approved drug "experimental" is legally limited. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal